The FY2025 (Dec) proxy of ARS Pharmaceuticals names 18 peer companies for pay. Among ARS Pharmaceuticals and these peers, CEO pay was 5th highest of 8 and total shareholder return was 5th highest of 8.
5th highest of 8in ARS Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:
$5.4M$27.8M
5th highest of 8in ARS Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:
$57$495
Pay peer group, FY2025 (Dec) proxy
| Cogent Biosciences | ||
| TG Therapeutics | ||
| Protagonist Therapeutics | ||
| Mirum Pharmaceuticals | ||
| Arcutis Biotherapeutics | ||
| Tarsus Pharmaceuticals | ||
| Agios Pharmaceuticals | ||
| Alector, Inc. | Not disclosed | Not disclosed |
| AnaptysBio, Inc. | Not disclosed | Not disclosed |
| Avadel Pharmaceuticals plc | Not disclosed | Not disclosed |
| Day One Biopharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Geron | Not disclosed | Not disclosed |
| Iovance Biotherapeutics, Inc. | Not disclosed | Not disclosed |
| Liquidia | Not disclosed | Not disclosed |
| Revance Therapeutics, Inc. | Not disclosed | Not disclosed |
| Rigel Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals | Not disclosed | Not disclosed |
| Viridian Therapeutics, Inc. | Not disclosed | Not disclosed |
18 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.